REYKJAVÍK, ICELAND, JANUARY 16, 2016 – Prof. Thorsteinn Loftsson, Oculis’ co-founder and Chief Scientific Officer, is on the recently published Thomson Reuters’ list of The World’s Most Influential Scientific Minds for 2015. This is the second year in a row Prof. Loftsson is included on Thomas Reuters’ list of leading researchers.
The list is a selection of around 3,000 influential researchers in their scientific fields according to Thomson Reuters. The list covers all field of science and disciplines except for humanities. The list can be found on http://highlycited.com/.
It is a unique achievement to make the list and confirms Prof. Loftsson’s status as a global leader in cyclodextrin based drug delivery.
Oculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery to the eye. Oculis has developed the solubilizing nanoparticle (SNP) drug delivery platform consisting of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The SNP platform provides sustained release over several hours and allows for greatly increased solubility of lipophilic drugs. Among the key advantages of the SNP platform is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application, i.e. an eye drop.
For further information on Oculis, please visit: http://www.oculispharma.com.